Correlation Between Keros Therapeutics and Pluri
Can any of the company-specific risk be diversified away by investing in both Keros Therapeutics and Pluri at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Keros Therapeutics and Pluri into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Keros Therapeutics and Pluri Inc, you can compare the effects of market volatilities on Keros Therapeutics and Pluri and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Keros Therapeutics with a short position of Pluri. Check out your portfolio center. Please also check ongoing floating volatility patterns of Keros Therapeutics and Pluri.
Diversification Opportunities for Keros Therapeutics and Pluri
-0.4 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Keros and Pluri is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding Keros Therapeutics and Pluri Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pluri Inc and Keros Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Keros Therapeutics are associated (or correlated) with Pluri. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pluri Inc has no effect on the direction of Keros Therapeutics i.e., Keros Therapeutics and Pluri go up and down completely randomly.
Pair Corralation between Keros Therapeutics and Pluri
Given the investment horizon of 90 days Keros Therapeutics is expected to generate 0.65 times more return on investment than Pluri. However, Keros Therapeutics is 1.54 times less risky than Pluri. It trades about 0.04 of its potential returns per unit of risk. Pluri Inc is currently generating about -0.04 per unit of risk. If you would invest 4,875 in Keros Therapeutics on August 24, 2024 and sell it today you would earn a total of 509.00 from holding Keros Therapeutics or generate 10.44% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Keros Therapeutics vs. Pluri Inc
Performance |
| Timeline |
| Keros Therapeutics |
| Pluri Inc |
Keros Therapeutics and Pluri Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Keros Therapeutics and Pluri
The main advantage of trading using opposite Keros Therapeutics and Pluri positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Keros Therapeutics position performs unexpectedly, Pluri can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pluri will offset losses from the drop in Pluri's long position.| Keros Therapeutics vs. ZyVersa Therapeutics | Keros Therapeutics vs. Sonnet Biotherapeutics Holdings | Keros Therapeutics vs. Zura Bio Limited | Keros Therapeutics vs. Phio Pharmaceuticals Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |